Need For Long-Term CV Studies Goes Beyond COX-2s – Celebrex Study Authors
This article was originally published in The Pink Sheet Daily
Executive Summary
Regulatory authorities should request long-term cardiovascular safety studies for any new drug that may be used in high-risk patients in light of the COX-2 safety signals, authors of aCelebrex study state